Literature DB >> 16680006

Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury.

David L Williams1, Tammy Ozment-Skelton, Chaunfu Li.   

Abstract

The phosphoinositide 3-kinases (PI3Ks) are a conserved family of signal transduction enzymes that are involved in regulating cellular activation, inflammatory responses, chemotaxis, and apoptosis. We have discovered that a carbohydrate ligand, glucan, will stimulate the endogenous PI3K/Akt signaling pathway. This article reviews the current data on the role of the PI3K/Akt signaling pathway as a negative feedback mechanism or compensatory regulator of septic and inflammatory responses. Of greater importance, the data reviewed in this article suggest that modulation of the PI3K/Akt signaling pathway can reduce the morbidity and mortality associated with septic and I/R injury. Thus, manipulation of the endogenous PI3K/Akt signaling pathway may represent a new and novel therapeutic approach to management of important diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16680006     DOI: 10.1097/01.shk.0000209542.76305.55

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  48 in total

1.  Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation.

Authors:  Hongkuan Fan; Donald Wong; Sarah H Ashton; Keith T Borg; Perry V Halushka; James A Cook
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

Review 2.  Toll-like receptors: new players in myocardial ischemia/reperfusion injury.

Authors:  Tuanzhu Ha; Li Liu; Jim Kelley; Race Kao; David Williams; Chuanfu Li
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

3.  Inhibition of glycogen synthase kinase 3 beta ameliorates liver ischemia reperfusion injury by way of an interleukin-10-mediated immune regulatory mechanism.

Authors:  Feng Ren; Zhongping Duan; Qiao Cheng; Xiuda Shen; Feng Gao; Li Bai; Jun Liu; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Yuan Zhai
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Toll-like receptor 4 plays a central role in cardiac dysfunction during trauma hemorrhage shock.

Authors:  Xia Zhang; Chen Lu; Ming Gao; Xinyun Cao; Tuanzhu Ha; John H Kalbfleisch; David L Williams; Chuanfu Li; Race L Kao
Journal:  Shock       Date:  2014-07       Impact factor: 3.454

5.  Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Michael O'Connor; Basilia Zingarelli
Journal:  Int J Clin Exp Med       Date:  2010-01-01

6.  Mechanism of the salutary effects of estrogen on kupffer cell phagocytic capacity following trauma-hemorrhage: pivotal role of Akt activation.

Authors:  Chi-Hsun Hsieh; Eike A Nickel; Jianguo Chen; Martin G Schwacha; Mashkoor A Choudhry; Kirby I Bland; Irshad H Chaudry
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 7.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

8.  Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

9.  Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-22

10.  The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs.

Authors:  Ariadne Androulidaki; Dimitrios Iliopoulos; Alicia Arranz; Christina Doxaki; Steffen Schworer; Vassiliki Zacharioudaki; Andrew N Margioris; Philip N Tsichlis; Christos Tsatsanis
Journal:  Immunity       Date:  2009-08-21       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.